{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T21:23:20Z","timestamp":1770413000385,"version":"3.49.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1038\/leu.2010.145","type":"journal-article","created":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T15:23:56Z","timestamp":1277997836000},"page":"1631-1640","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Long-term exposure of leukemia cells to multi-targeted tyrosine kinase inhibitor induces activations of AKT, ERK and STAT5 signaling via epigenetic silencing of the PTEN gene"],"prefix":"10.1038","volume":"24","author":[{"given":"C","family":"Nishioka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Ikezoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,7,1]]},"reference":[{"key":"BFleu2010145_CR1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-3565(24)38879-2","volume":"295","author":"E Buchdunger","year":"2000","unstructured":"Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139\u2013145.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFleu2010145_CR2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561\u2013566.","journal-title":"Nat Med"},{"key":"BFleu2010145_CR3","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1182\/blood-2004-10-3967","volume":"105","author":"AL Dewar","year":"2005","unstructured":"Dewar AL, Cambareri AC, Zannettino AC, Miller BL, Doherty KV, Hughes TP et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 2005; 105: 3127\u20133132.","journal-title":"Blood"},{"key":"BFleu2010145_CR4","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V96.3.925","volume":"96","author":"MC Heinrich","year":"2000","unstructured":"Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ . Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000; 96: 925\u2013932.","journal-title":"Blood"},{"key":"BFleu2010145_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/sj.leu.2403241","volume":"18","author":"LS Steelman","year":"2004","unstructured":"Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA . JAK\/STAT, Ras\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004; 18: 189\u2013218.","journal-title":"Leukemia"},{"key":"BFleu2010145_CR6","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMoa011573","volume":"346","author":"H Kantarjian","year":"2002","unstructured":"Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645\u2013652.","journal-title":"N Engl J Med"},{"key":"BFleu2010145_CR7","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994\u20131004.","journal-title":"N Engl J Med"},{"key":"BFleu2010145_CR8","doi-asserted-by":"publisher","first-page":"6247","DOI":"10.1158\/1078-0432.CCR-05-0882","volume":"11","author":"M Talpaz","year":"2005","unstructured":"Talpaz M, Rakhit A, Rittweger K, O\u2019Brien S, Cortes J, Fettner S et al. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia. Clin Cancer Res 2005; 11: 6247\u20136255.","journal-title":"Clin Cancer Res"},{"key":"BFleu2010145_CR9","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1182\/blood-2006-02-004325","volume":"108","author":"HM Kantarjian","year":"2006","unstructured":"Kantarjian HM, Talpaz M, O\u2019Brien S, Jones D, Giles F, Garcia-Manero G et al. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 2006; 108: 1835\u20131840.","journal-title":"Blood"},{"key":"BFleu2010145_CR10","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1056\/NEJMoa020150","volume":"347","author":"JF Apperley","year":"2002","unstructured":"Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002; 347: 481\u2013487.","journal-title":"N Engl J Med"},{"key":"BFleu2010145_CR11","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/j.1365-2141.2008.07033.x","volume":"141","author":"G Helbig","year":"2008","unstructured":"Helbig G, Stella-Ho\u0142owiecka B, Majewski M, Ca\u0142becka M, Gajkowska J, Klimkiewicz R et al. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFR\u03b1-expressing patients. Br J Haematol 2008; 141: 200\u2013204.","journal-title":"Br J Haematol"},{"key":"BFleu2010145_CR12","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.1182\/blood-2006-10-050054","volume":"109","author":"JV Jovanovic","year":"2007","unstructured":"Jovanovic JV, Score J, Waghorn K, Cilloni D, Gottardi E, Metzgeroth G et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFR\u03b1-positive chronic eosinophilic leukemia. Blood 2007; 109: 4635\u20134640.","journal-title":"Blood"},{"key":"BFleu2010145_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/00062752-200401000-00008","volume":"11","author":"J Cools","year":"2004","unstructured":"Cools J, Stover EH, Wlodarska I, Marynen P, Gilliland DG . The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. Curr Opin Hematol 2004; 11: 51\u201357.","journal-title":"Curr Opin Hematol"},{"key":"BFleu2010145_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.drup.2005.04.005","volume":"8","author":"J Cools","year":"2005","unstructured":"Cools J, Maertens C, Marynen P . Resistance to tyrosine kinase inhibitors: calling on extra forces. Drug Resist Updat 2005; 8: 119\u2013129.","journal-title":"Drug Resist Updat"},{"key":"BFleu2010145_CR15","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa025217","volume":"348","author":"J Cools","year":"2003","unstructured":"Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201\u20131204.","journal-title":"N Engl J Med"},{"key":"BFleu2010145_CR16","doi-asserted-by":"publisher","first-page":"7830","DOI":"10.1073\/pnas.0932698100","volume":"100","author":"JH Griffin","year":"2003","unstructured":"Griffin JH, Leung J, Bruner RJ, Caligiuri MA, Briesewitz R . Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci USA 2003; 100: 7830\u20137835.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2010145_CR17","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/sj.leu.2403600","volume":"19","author":"N von Bubnoff","year":"2005","unstructured":"von Bubnoff N, Sandherr M, Schlimok G, Andreesen R, Peschel C, Duyster J . Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia. Leukemia 2005; 19: 286\u2013287.","journal-title":"Leukemia"},{"key":"BFleu2010145_CR18","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876\u2013880.","journal-title":"Science"},{"key":"BFleu2010145_CR19","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1126\/science.275.5308.1943","volume":"275","author":"J Li","year":"1997","unstructured":"Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI . PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943\u20131947.","journal-title":"Science"},{"key":"BFleu2010145_CR20","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nrc1819","volume":"6","author":"M Cully","year":"2006","unstructured":"Cully M, You H, Levine AJ, Mak TW . Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev 2006; 6: 184\u2013192.","journal-title":"Nat Rev"},{"key":"BFleu2010145_CR21","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/nature04747","volume":"441","author":"J Zhang","year":"2006","unstructured":"Zhang J, Grindley JC, Yin T, Jayasinghe S, He XC, Ross JT et al. PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 2006; 441: 518\u2013522.","journal-title":"Nature"},{"key":"BFleu2010145_CR22","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00011-008-8053-2","volume":"57","author":"DZ Shao","year":"2008","unstructured":"Shao DZ, Lin M . Platonin inhibits LPS-induced NF-\u03baB by preventing activation of Akt and IKK\u03b2 in human PBMC. Inflamm Res 2008; 57: 601\u2013606.","journal-title":"Inflamm Res"},{"key":"BFleu2010145_CR23","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","volume":"129","author":"BD Manning","year":"2007","unstructured":"Manning BD, Cantley LC . AKT\/PKB signaling: navigating downstream. Cell 2007; 129: 1261\u20131274.","journal-title":"Cell"},{"key":"BFleu2010145_CR24","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.lungcan.2005.10.003","volume":"51","author":"JM Tang","year":"2006","unstructured":"Tang JM, He QY, Guo RX, Chang XJ . Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confer poor prognosis. Lung Cancer 2006; 51: 181\u2013191.","journal-title":"Lung Cancer"},{"key":"BFleu2010145_CR25","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1200\/JCO.2004.12.002","volume":"22","author":"G Bepler","year":"2004","unstructured":"Bepler G, Sharma S, Cantor A, Gautam A, Haura E, Simon G et al. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22: 1878\u20131885.","journal-title":"J Clin Oncol"},{"key":"BFleu2010145_CR26","first-page":"773","volume":"15","author":"L Sui","year":"2006","unstructured":"Sui L, Dong Y, Watanabe Y, Yamaguchi F, Sugimoto K, Tokuda M . Alteration and clinical relevance of PTEN expression and its correlation with survivin expression in epithelial ovarian tumors. Oncol Rep 2006; 15: 773\u2013778.","journal-title":"Oncol Rep"},{"key":"BFleu2010145_CR27","doi-asserted-by":"publisher","first-page":"7564","DOI":"10.1073\/pnas.0702507104","volume":"104","author":"LH Saal","year":"2007","unstructured":"Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 2007; 104: 7564\u20137569.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2010145_CR28","doi-asserted-by":"publisher","first-page":"5246","DOI":"10.1073\/pnas.95.9.5246","volume":"95","author":"YE Whang","year":"1998","unstructured":"Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL et al. Inactivation of the tumor suppressor PTEN\/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 1998; 95: 5246\u20135250.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2010145_CR29","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/hmg\/8.2.185","volume":"8","author":"PL Dahia","year":"1999","unstructured":"Dahia PL, Aguiar RC, Alberta J, Kum JB, Caron S, Sill H et al. PTEN is inversely correlated with the cell survival factor Akt\/PKB and is inactivated via multiple mechanisms in haematological malignancies. Hum Mol Genet 1999; 8: 185\u2013193.","journal-title":"Hum Mol Genet"},{"key":"BFleu2010145_CR30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/1097-0215(20010101)91:1<22::AID-IJC1002>3.0.CO;2-S","volume":"91","author":"HB Salvesen","year":"2001","unstructured":"Salvesen HB, MacDonald N, Ryan A, Jacobs IJ, Lynch ED, Akslen LA et al. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer 2001; 91: 22\u201326.","journal-title":"Int J Cancer"},{"key":"BFleu2010145_CR31","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/sj.leu.2404622","volume":"21","author":"C Nishioka","year":"2007","unstructured":"Nishioka C, Ikezoe T, Yang J, Koeffler HP, Taguchi H . Fludarabine induces apoptosis of human T-cell leukemia virus type 1-infected T cells via inhibition of the nuclear factor-kappaB signal pathway. Leukemia 2007; 21: 1044\u20131049.","journal-title":"Leukemia"},{"key":"BFleu2010145_CR32","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1182\/blood.V96.10.3553","volume":"96","author":"T Ikezoe","year":"2000","unstructured":"Ikezoe T, Daar ES, Hisatake J, Taguchi H, Koeffler HP . HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells. Blood 2000; 96: 3553\u20133559.","journal-title":"Blood"},{"key":"BFleu2010145_CR33","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.1182\/blood-2007-06-098079","volume":"111","author":"C Nishioka","year":"2008","unstructured":"Nishioka C, Ikezoe T, Yang J, Miwa A, Tasaka T, Kuwayama Y et al. Ki11502, a novel multi-targeted receptor tyrosine kinase inhibitor, induces growth arrest and apoptosis of human leukemia cells in vitro and in vivo. Blood 2008; 111: 5086\u20135092.","journal-title":"Blood"},{"key":"BFleu2010145_CR34","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1182\/blood-2003-07-2203","volume":"104","author":"T Ikezoe","year":"2004","unstructured":"Ikezoe T, Tanosaki S, Krug U, Liu B, Cohen P, Taguchi H et al. Insulin-like growth factor binding protein-3 antagonizes the effects of retinoids in myeloid leukemia cells. Blood 2004; 104: 237\u2013242.","journal-title":"Blood"},{"key":"BFleu2010145_CR35","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/1097-0215(20010101)91:1<22::AID-IJC1002>3.0.CO;2-S","volume":"91","author":"HB Salvesen","year":"2001","unstructured":"Salvesen HB, MacDonald N, Ryan A, Jacobs IJ, Lynch ED, Akslen LA et al. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer 2001; 91: 22\u201326.","journal-title":"Int J Cancer"},{"key":"BFleu2010145_CR36","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1002\/ijc.24377","volume":"125","author":"C Nishioka","year":"2009","unstructured":"Nishioka C, Ikezoe T, Yang J, Komatsu N, Koeffler HP, Yokoyama A . Blockade of MEK signaling potentiates 5-Aza-2\u2032-deoxycytidine-induced apoptosis and upregulation of p21(waf1) in acute myelogenous leukemia cells. Int J Cancer 2009; 125: 1168\u20131176.","journal-title":"Int J Cancer"},{"key":"BFleu2010145_CR37","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0960-9822(00)00310-9","volume":"10","author":"A Shimamura","year":"2000","unstructured":"Shimamura A, Ballif BA, Richards SA, Blenis J . Rsk1 mediates a MEK\u2013MAP kinase cell survival signal. Curr Biol 2000; 10: 127\u2013135.","journal-title":"Curr Biol"},{"key":"BFleu2010145_CR38","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1038\/sj.onc.1203418","volume":"19","author":"SC Rosa Santos","year":"2000","unstructured":"Rosa Santos SC, Dumon S, Mayeux P, Gisselbrecht S, Gouilleux F . Cooperation between STAT5 and phosphatidylinositol 3-kinase in the IL-3-dependent survival of a bone marrow derived cell line. Oncogene 2000; 19: 1164\u20131172.","journal-title":"Oncogene"},{"key":"BFleu2010145_CR39","doi-asserted-by":"publisher","first-page":"138","DOI":"10.2174\/156652408783769580","volume":"8","author":"MR Warr","year":"2008","unstructured":"Warr MR, Shore GC . Unique biology of Mcl-1: therapeutic opportunities in cancer. Curr Mol Med 2008; 8: 138\u2013147.","journal-title":"Curr Mol Med"},{"key":"BFleu2010145_CR40","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1016\/j.leukres.2010.02.024","volume":"34","author":"T Ikezoe","year":"2010","unstructured":"Ikezoe T, Tasaka T, Nishioka C, Yokoyama A . Successful treatment of imatinib-resistant hypereosinophilic syndrome with nilotinib. Leuk Res 2010; 34: e200\u2013e201.","journal-title":"Leuk Res"},{"key":"BFleu2010145_CR41","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.leukres.2009.09.026","volume":"34","author":"H de Lavallade","year":"2010","unstructured":"de Lavallade H, Finetti P, Carbuccia N, Khorashad JS, Charbonnier A, Foroni L et al. A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia. Leuk Res 2010; 34: 254\u2013257.","journal-title":"Leuk Res"},{"key":"BFleu2010145_CR42","first-page":"1157","volume":"31","author":"R Noro","year":"2007","unstructured":"Noro R, Gemma A, Miyanaga A, Kosaihira S, Minegishi Y, Nara M et al. PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors. Int J Oncol 2007; 31: 1157\u20131163.","journal-title":"Int J Oncol"},{"key":"BFleu2010145_CR43","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1038\/sj.bjc.6602559","volume":"92","author":"Y Kokubo","year":"2005","unstructured":"Kokubo Y, Gemma A, Noro R, Seike M, Kataoka K, Matsuda K et al. Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Br J Cancer 2005; 92: 1711\u20131719.","journal-title":"Br J Cancer"},{"key":"BFleu2010145_CR44","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/1756-9966-28-123","volume":"28","author":"HQ Zhuang","year":"2009","unstructured":"Zhuang HQ, Wang J, Yuan ZY, Zhao LJ, Wang P, Wang CL . The drug-resistance to gefitinib in PTEN low expression cancer cells is reversed by irradiation in vitro. J Exp Clin Cancer Res 2009; 28: 123.","journal-title":"J Exp Clin Cancer Res"},{"key":"BFleu2010145_CR45","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/pros.20745","volume":"68","author":"Z Wu","year":"2008","unstructured":"Wu Z, Gioeli D, Conaway M, Weber MJ, Theodorescu D . Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors. Prostate 2008; 68: 935\u2013944.","journal-title":"Prostate"},{"key":"BFleu2010145_CR46","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1038\/leu.2009.163","volume":"23","author":"C Nishioka","year":"2009","unstructured":"Nishioka C, Ikezoe T, Yang J, Yokoyama A . Multitargeted tyrosine kinase inhibitor stimulates expression of IL-6 and activates JAK2\/STAT5 signaling in acute myelogenous leukemia cells. Leukemia 2009; 23: 2304\u20132308.","journal-title":"Leukemia"},{"key":"BFleu2010145_CR47","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nature07618","volume":"457","author":"A Viale","year":"2009","unstructured":"Viale A, De Franco F, Orleth A, Cambiaghi V, Giuliani V, Bossi D et al. Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature 2009; 457: 51\u201356.","journal-title":"Nature"},{"key":"BFleu2010145_CR48","doi-asserted-by":"publisher","first-page":"16220","DOI":"10.1073\/pnas.252462599","volume":"99","author":"ML Guzman","year":"2002","unstructured":"Guzman ML, Swiderski CF, Howard DS, Grimes BA, Rossi RM, Szilvassy SJ et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA 2002; 99: 16220\u201316225.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2010145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2010145","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2010145.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T12:55:36Z","timestamp":1740228936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2010145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,1]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["BFleu2010145"],"URL":"https:\/\/doi.org\/10.1038\/leu.2010.145","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,1]]},"assertion":[{"value":"4 January 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2010","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}